Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

921
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
921
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

732
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
732
Chemical Synapses01:26

Chemical Synapses

8.8K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
8.8K
Muscle Contraction01:15

Muscle Contraction

90.5K
 
90.5K
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

151
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
151

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Differing Phenotypes of the Three Most Common Postsynaptic Congenital Myasthenic Syndromes Governed by Their Underlying Molecular Pathogenic Mechanisms.

Muscle & nerve·2026
Same author

Genetic mimics of neuromyelitis optica spectrum disorder.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Positive allosteric modulator selective for adult muscle nicotinic acetylcholine receptor.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Protocol for stable cell line production to express muscle-type nicotinic receptor.

STAR protocols·2026
Same author

Optimal strategies for treatment discontinuation in MOG antibody-associated disease.

Brain : a journal of neurology·2026
Same author

Congenital myasthenic syndrome: is it time for a name change to genetic myasthenic syndrome?

Brain : a journal of neurology·2026

Related Experiment Video

Updated: Jun 19, 2025

Measuring Neuromuscular Junction Functionality
10:40

Measuring Neuromuscular Junction Functionality

Published on: August 6, 2017

18.0K

Congenital myasthenic syndromes: increasingly complex.

Sithara Ramdas1,2, David Beeson3, Yin Yao Dong3

  • 1MDUK Neuromuscular Centre, Department of Paediatrics, University of Oxford.

Current Opinion in Neurology
|July 25, 2024
PubMed
Summary

Congenital myasthenia syndromes (CMS) involve complex genetic mutations affecting neuromuscular transmission. New therapies must address multisystem issues beyond muscle weakness for better patient outcomes.

More Related Videos

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

15.3K
Characterization of Neuromuscular Junctions in Mice by Combined Confocal and Super-Resolution Microscopy
11:03

Characterization of Neuromuscular Junctions in Mice by Combined Confocal and Super-Resolution Microscopy

Published on: December 8, 2021

3.7K

Related Experiment Videos

Last Updated: Jun 19, 2025

Measuring Neuromuscular Junction Functionality
10:40

Measuring Neuromuscular Junction Functionality

Published on: August 6, 2017

18.0K
Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

15.3K
Characterization of Neuromuscular Junctions in Mice by Combined Confocal and Super-Resolution Microscopy
11:03

Characterization of Neuromuscular Junctions in Mice by Combined Confocal and Super-Resolution Microscopy

Published on: December 8, 2021

3.7K

Area of Science:

  • Neurology
  • Genetics
  • Molecular Biology

Background:

  • Congenital myasthenia syndromes (CMS) are inherited disorders impacting neuromuscular transmission.
  • Understanding CMS is complex due to the increasing number of implicated proteins.

Purpose of the Study:

  • To review the evolving understanding of congenital myasthenia syndromes.
  • To highlight the complexity introduced by novel gene discoveries in CMS.

Main Methods:

  • Review of recent scientific literature on congenital myasthenia syndromes.
  • Analysis of next-generation sequencing findings in CMS.

Main Results:

  • Novel mutations in genes with wide expression profiles are identified in CMS.
  • These mutations lead to broader phenotypic spectra beyond neuromuscular junction defects.
  • Defective neuromuscular transmission is a common feature, but not the sole manifestation.

Conclusions:

  • Emerging CMS forms present non-neuromuscular phenotypes requiring broader therapeutic strategies.
  • Disease-modifying treatments are needed to address multisystem involvement.
  • Despite effective treatments for many, a subset of CMS patients still requires more efficacious therapies.